Gilead Sciences (GILD) Shareholder Wilsey Asset Management Has Upped Its Position by $418,119; Transcanada (TRP) Stock Value Declined While Intact Investment Management Has Increased Its Holding

May 22, 2018 - By Migdalia James

TransCanada Corporation (NYSE:TRP) Logo

Intact Investment Management Inc increased its stake in Transcanada Corp (TRP) by 79.12% based on its latest 2017Q4 regulatory filing with the SEC. Intact Investment Management Inc bought 209,800 shares as the company’s stock declined 16.00% with the market. The institutional investor held 474,980 shares of the natural gas distribution company at the end of 2017Q4, valued at $29.05M, up from 265,180 at the end of the previous reported quarter. Intact Investment Management Inc who had been investing in Transcanada Corp for a number of months, seems to be bullish on the $38.90 billion market cap company. The stock increased 0.64% or $0.2765 during the last trading session, reaching $43.5165. About 148,617 shares traded. TransCanada Corporation (NYSE:TRP) has declined 12.65% since May 22, 2017 and is downtrending. It has underperformed by 24.20% the S&P500.




Wilsey Asset Management Inc increased its stake in Gilead Sciences Inc (GILD) by 5.07% based on its latest 2017Q4 regulatory filing with the SEC. Wilsey Asset Management Inc bought 5,889 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 122,092 shares of the health care company at the end of 2017Q4, valued at $8.75M, up from 116,203 at the end of the previous reported quarter. Wilsey Asset Management Inc who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $88.11B market cap company. The stock increased 0.19% or $0.131 during the last trading session, reaching $67.761. About 710,214 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 22, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was upgraded by Wells Fargo to “Outperform” on Tuesday, January 16. Morgan Stanley maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, May 2. Morgan Stanley has “Equal-Weight” rating and $81 target. The rating was maintained by Morgan Stanley on Wednesday, February 7 with “Equal-Weight”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by Jefferies on Wednesday, October 4. Mizuho maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Sunday, October 29 with “Buy” rating. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, May 2. Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, September 14 with “Outperform” rating. RBC Capital Markets maintained the shares of GILD in report on Monday, October 3 with “Outperform” rating. Robert W. Baird maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, September 15. Robert W. Baird has “Buy” rating and $87.0 target. Jefferies maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, October 27. Jefferies has “Hold” rating and $87.0 target.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead Sciences: Resist Sentiment, Stop Speculating And Invest” on May 15, 2018, also Seekingalpha.com with their article: “Gilead: Where’s The Next Catalyst?” published on May 18, 2018, Seekingalpha.com published: “Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)” on May 16, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead: What A Disaster” published on May 08, 2018 as well as Seekingalpha.com‘s news article titled: “Gilead: I’m Thankful That I Sold” with publication date: May 07, 2018.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It is negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Moreover, Cap City Tru Fl has 0.14% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Creative Planning has 0.06% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Bb Biotech Ag owns 2.77M shares or 5.6% of their US portfolio. Howard Hughes Med Institute holds 50,000 shares or 0.93% of its portfolio. 11,927 were accumulated by Orleans Cap La. C Grp Holdings A S has invested 0.36% in Gilead Sciences, Inc. (NASDAQ:GILD). Leuthold Limited Liability Com invested in 0.68% or 95,395 shares. Capital Ca reported 0.38% in Gilead Sciences, Inc. (NASDAQ:GILD). Selway Asset Mgmt has 19,650 shares for 0.83% of their portfolio. Baxter Bros stated it has 4,160 shares. Chickasaw Capital Management Limited Liability Company holds 0.03% or 22,100 shares. Caisse De Depot Et Placement Du Quebec accumulated 1.81 million shares. Rathbone Brothers Public Ltd Company owns 14,081 shares for 0.04% of their portfolio. Wilsey Asset Mngmt owns 4.91% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 122,092 shares. Griffin Asset Mgmt stated it has 27,160 shares.

Since January 2, 2018, it had 0 insider buys, and 22 selling transactions for $44.80 million activity. $467,138 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Cogan John Francis. The insider Alton Gregg H sold 15,000 shares worth $1.11 million. $3.93M worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by MARTIN JOHN C. WILSON GAYLE E sold $4.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, February 9. 5,000 shares valued at $401,566 were sold by Washington Robin L on Wednesday, February 21.

Among 13 analysts covering TransCanada Corporation (NYSE:TRP), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. TransCanada Corporation had 29 analyst reports since August 4, 2015 according to SRatingsIntel. As per Wednesday, December 2, the company rating was upgraded by Macquarie Research. JP Morgan initiated TransCanada Corporation (NYSE:TRP) on Tuesday, December 15 with “Overweight” rating. IBC upgraded TransCanada Corporation (NYSE:TRP) on Monday, December 7 to “Sector Outperform” rating. The company was downgraded on Thursday, March 22 by Wells Fargo. On Thursday, January 11 the stock rating was upgraded by Morgan Stanley to “Buy”. The rating was downgraded by TheStreet to “Buy” on Saturday, August 15. The stock of TransCanada Corporation (NYSE:TRP) earned “Equal-Weight” rating by Barclays Capital on Monday, May 2. On Thursday, August 6 the stock rating was downgraded by Zacks to “Hold”. As per Friday, March 23, the company rating was maintained by Morgan Stanley. The firm earned “Outperform” rating on Wednesday, November 4 by RBC Capital Markets.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.